Zodasiran

2 papers4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Human trial1

Outcomes

Hepatotoxicity

no changein humans1

1 study

Zodasiran has no effect on hepatotoxicity in humans.
“Safety was favorable, with no significant hepatotoxicity or liver fat accumulation.”
Human trialin patients with dyslipidemiaGalNAc conjugate
RNA INTERFERENCE OF ANGPTL3 VIA ZODASIRAN: A NEXT-GENERATION APPROACH FOR TREATING ATHEROGENIC DYSLIPIDEMIA
AHA Scientific Sessions 2025 abstract3 Nov 2025

Apolipoprotein B

downin humans1

1 study

Zodasiran decreases Apolipoprotein B in humans.
“Zodasiran induced dose-dependent, sustained reductions in triglycerides, LDL-C, non-HDL-C, apolipoprotein B, and remnant cholesterol.”
Human trialin patients with dyslipidemiaGalNAc conjugate
RNA INTERFERENCE OF ANGPTL3 VIA ZODASIRAN: A NEXT-GENERATION APPROACH FOR TREATING ATHEROGENIC DYSLIPIDEMIA
AHA Scientific Sessions 2025 abstract3 Nov 2025